Invitation to telephone conference due to Recipharm’s acquisition of Lusomedicamenta

The contract development and manufacturing organisation, Recipharm AB acquired
yesterday 13 November the Lisbon based CDMO Lusomedicameta Sociedade Técnica
Farmacêutica S.A for SEK 1 billion.
Due to the announcement of the acquisition yesterday a telephone conference with
a web presentation and Q&A will be held today at 09:00 am CET.

Yesterday’s press release in full is attached through the link at the end of
this announcement.

To participate in the conference, please dial:
From Sweden, tel: +46 8 506 443 86
From Denmark, tel: +45 32 71 42 62
From Finland, tel: +358 9 8171 0375
From Norway, tel: +47 21 06 61 13
From the UK, tel: +44 20 7153 9154
From Germany, tel: +49 69 2017 44 210
From France, tel: +33 1 70 70 95 02
From Spain, tel: +34 914 142 009
From Switzerland, tel: +41 44 580 65 22
From the US, tel:+1 877 423 0830
From Italy, tel: + +39 02 3600 6663
From Portugal: +49 69 20 17 44 210

Pin code for participants: 862216#

To access the presentation use the following link:
http://event.onlineseminarsolutions.com/r.htm?e=886795&s=1&k=805E770D4F476C044CC
E 
2004D68E488F

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10

Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material including API and
pharmaceutical product development. Recipharm manufactures more than 250
different products to customers ranging from Big Pharma through to smaller
research- and development companies. Recipharm’s turnover is approximately SEK
2.6 billion and the Company operates development and manufacturing facilities in
Sweden, France, the UK, Germany, Spain and Italy and is headquartered in
Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX
Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden Telephone 46 8 602 52 00
Fax 46 8 81 87 03, www.recipharm.com